Radyus Research and Eurofins CDMO Alphora announced a new strategic partnership to help accelerate early-stage drug development for biotech companies worldwide.
The partnership is built on a shared commitment to operational R&D excellence through long-term client collaborations. By integrating capabilities from preclinical development through clinical proof-of-concept, Radyus and Alphora aim to create a combined services offering to help clients reduce inefficiencies, eliminate handoffs, and improve the likelihood of drug program success.
Radyus Research will contribute deep expertise in drug development strategy, efficacy and safety animal testing, regulatory planning, clinical trial operations and cross-functional program management. Eurofins CDMO Alphora will serve as the partnership's manufacturing engine, with a strong record in process development and GMP manufacturing for small molecule APIs, biologics and drug products.
"We're excited to launch this partnership and unlock the value for our clients," said Marta New, CEO of Radyus Research. "It reflects our joint belief that long-term collaboration, rather than transactional engagement, is the key to efficient drug development. Together, we're surrounding our clients with a world-class, globally connected operating teams committed to delivering great results."
"This alliance with Radyus enhances our ability to deliver cohesive strategies and executional excellence across the development continuum," Eurofins CDMO Alphora notes. "Together, we're building a high-trust model that reflects the collaborative, global nature of today's biopharmaceutical industry."